Nephrology Dialysis Transplantation, Vol 13, Issue 11 2890-2893, Copyright © 1998 by Oxford University Press
D Ducloux, C Ruedin, R Gibey, P Vautrin, C Bresson-Vautrin, J Rebibou and J Chalopin
Background: Previous studies have demonstrated that
hyperhomocyst(e)inaemia is present in patients with impaired renal function
and is correlated with cardiovascular disease. Because conflicting data are
available on the prevalence, determinants, and clinical significance of
hyperhomocyst(e)inaemia in renal-transplant recipients, we conducted the
largest cross-sectional study on homocysteine determinants and clinical
correlates in renal transplant recipients. Methods:
Plasma homocyst(e)ine concentrations and factors known to influence
homocysteine metabolism were analysed in 224 renal transplant recipients.
Atherosclerotic complications were evaluated with respect to plasma
homocysteine concentrations. Results: Mean plasma
homocyst(e)ine was 21.3±9.7 &mgr;mol/l. After adjusting for
age, gender, transplant duration and creatinine clearance, patients with
and without cyclosporin A (CsA) had similar plasma homocyst(e)ine
concentrations (16.9±5.9 &mgr;mol/l in CsA(+) patients
vs 16.3±5.2 &mgr;mol/l in CsA(-)
patients; P=0.3). We found a significant inverse relationship between
plasma homocyst(e)ine and folate concentrations in both CsA(+) (r=-0.243;
P<0.005) and CsA(-) (r=-0.396; P<0.05) patients. Patients
with a past history of cardiovascular events had higher plasma
homocyst(e)ine concentrations (25.2±11.7 mmol/l
vs 20.5±8.8 mmol/l; P<0.005).
Conclusion: Homocyst(e)inaemia is closely related to
renal function and folate concentration in renal-transplant recipients. CsA
does not seem to have direct effects on homocysteine metabolism.
Hyperhomocyst(e)inaemia is associated with cardiovascular disease in
renal-transplant recipients. Prospective placebo-controlled
homocysteine-lowering therapy studies are required in this patient
category. Key words: renal transplantation;
homocysteine; cyclosporin
ORIGINAL ARTICLES
Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients
Departments of Nephrology and Renal Transplantation, and Biochemistry, Hopital Saint Jacques, Besançon, France; Corresponding author
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Fernandez-Miranda, M. Sanz, A. de la Calle, C. Loinaz, P. Gomez, P. Diaz-Rubio, A. G. de la Camara, and E. Moreno Determinants of Increased Plasma Homocysteine in 221 Stable Liver Transplant Patients Clin. Chem., November 1, 2001; 47(11): 2037 - 2040. [Full Text] [PDF]
|
|
|
|
|
|
O. Aras, M. Y. Tsai, N. Q. Hanson, R. Bailey, G. Rao, and D. B. Hunninghake Cystatin C Is an Independent Predictor of Fasting and Post-Methionine Load Total Homocysteine Concentrations among Stable Renal Transplant Recipients Clin. Chem., July 1, 2001; 47(7): 1263 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. KASISKE, M. A. VAZQUEZ, W. E. HARMON, R. S. BROWN, G. M. DANOVITCH, R. S. GASTON, D. ROTH, J. D. SCANDLING JR., and G. G. SINGER Recommendations for the Outpatient Surveillance of Renal Transplant Recipients J. Am. Soc. Nephrol., October 1, 2000; 11 (90001): S1 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. DUCLOUX, G. MOTTE, B. CHALLIER, R. GIBEY, and J.-M. CHALOPIN Serum Total Homocysteine and Cardiovascular Disease Occurrence in Chronic, Stable Renal Transplant Recipients: A ProspectiveStudy J. Am. Soc. Nephrol., January 1, 2000; 11(1): 134 - 137. [Abstract] [Full Text]
|
|